The US Food and Drug Administration (FDA) has approved Eli Lilly's new weight loss pill, Foundayo, introducing a more flexible oral option to the booming GLP-1 drug market. The approval, granted on 1 April, positions Lilly to compete directly with Novo Nordisk, the maker of injectable treatments Wegovy and Ozempic and the oral medication Rybelsus.
Foundayo is indicated for adults with obesity, those who are overweight, or individuals with weight-related health conditions. A key differentiator is its administration: unlike Rybelsus, which must be taken each morning on an empty stomach, Foundayo can be taken at any time of day without food or water restrictions.
Clinical Performance and Market Impact
In a Lilly-funded trial published by The Lancet, Foundayo demonstrated significant weight loss results. Patients taking 12 to 36 milligrams of orforglipron, the pill's active ingredient, lost an average of 15 to 20 pounds. This outperformed patients on 7 to 14 milligrams of Novo Nordisk's Rybelsus, who lost an average of 8 to 11 pounds.
Lead trial investigator Dr. Julio Rosenstock stated the pill "outperformed" Rybelsus "on every key endpoint we measured, including A1C and weight loss." In a separate report, Lilly noted adults on the highest dose of Foundayo lost an average of 27 pounds.
The approval intensifies competition in a market revolutionised by GLP-1 drugs. These medications, initially for type 2 diabetes, are now used for conditions like polycystic ovarian syndrome (PCOS) and obstructive sleep apnea. Novo Nordisk released oral Wegovy for weight loss in early 2026 and plans a pill form of Ozempic.
Insurance Hurdles and Cost Considerations
Insurance coverage for Foundayo will be inconsistent. Private insurers and employers set their own rules, with many covering GLP-1s only for type 2 diabetes. Weight-loss patients often require prior authorisation or must complete health assessments.
Government plans like Medicare and Medicaid typically exclude weight-loss drugs, limiting coverage largely to diabetic patients. Lilly stated Medicare Part D enrollees may access the pill for $50 monthly from 1 July, though Medicare has not confirmed coverage. Insurers will finalise 2027 coverage decisions this summer.
The landscape is shifting, however. A GoodRx analysis found the number of Americans without coverage for Lilly's injectable Zepbound grew by 12% from 2025 to 2026, with over 16 million privately insured individuals lacking weight-loss coverage this year.
Lilly priced the highest dose of Foundayo at $349. The lowest dose costs $149 via self-pay or $25 with commercial insurance and a savings card. By comparison, high-dose oral Wegovy costs $299.
Side Effects and Direct-to-Consumer Shift
Common side effects of Foundayo include nausea, constipation, diarrhoea, and fatigue. Rare but serious risks include pancreatitis and severe stomach problems. Lilly advises taking only one pill daily under medical supervision and avoiding use with other GLP-1s.
Notably, trial participants on Foundayo experienced more side effects and were less likely to remain on the medication than those on Rybelsus.
The rise of GLP-1s has fuelled a direct-to-consumer (DTC) market. LillyDirect, the company's platform, partners with Walmart, Amazon, and telehealth provider Ro. Amanda Nguyen, GoodRx's senior health economist, noted "more consumers are exploring things like a cash option, bypassing insurance." UBS Investment Bank analysts predict the DTC channel will be the largest for Foundayo distribution.
Long-Term Implications and Future Battles
GLP-1s are a relatively new treatment class with limited long-term data. Ongoing studies explore their potential for heart disease, addiction, and arthritis. Maintaining weight loss likely requires long-term use, which economists say could be costly but may reduce future healthcare expenses by preventing obesity-related diseases.
The core conflict between soaring drug demand and rising healthcare costs is set to escalate. "Someone has to foot the bill," the report concludes, signalling continued battles between drugmakers, insurers, employers, and patients over who pays for these transformative treatments.